Dr. Inhye Ahn, MD

Dr. Ahn practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Ahn's NPI, 1053632984, was assigned on June 15, 2010. Dr. Ahn holds Massachusetts license 287006.

Dr. Ahn's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Ahn's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Ahn is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ahn practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Ahn's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Ahn is licensed in Massachusetts.

CMS data shows 320 Medicare services from Dr. Ahn across 6 procedure codes in 2024, for 151 Medicare patients. Medicare paid $31,194 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 151 Medicare patients who saw Dr. Ahn in 2024. The largest group is 65 to 74, with 86 patients. 68% of them have high cholesterol, and 65% have high blood pressure. 8% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ahn's median patient age at 70, with 45% women.

In 2024, Dr. Ahn wrote 107 Medicare Part D claims for 27 patients. 41% of them were for generic drugs. CMS names the drug for 55 of them, across 2 drugs with 11 or more claims each, at $813,950 in total drug cost. In 2023, CMS named 101 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ahn for performance year 2024, reported as part of a group. Dr. Ahn accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ahn as offering telehealth.

Dmand AI links 48 papers to Dr. Ahn, published from 2013 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors and Adenine. Dr. Ahn has published most often in Blood. Dr. Ahn's most frequent co-authors are Matthew S. Davids, MD, Philippe Armand, MD, PhD and David Christopher Fisher, MD.

Dmand AI links Dr. Ahn to 5 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Chromosome 17 deletion. National Heart, Lung, and Blood Institute (NHLBI) sponsors the most, 3.

CMS Open Payments shows 17 general payments to Dr. Ahn from 6 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 97% of the total. Eli Lilly and Company paid the most, $12,498. It also lists 3 research payments totaling $557,164 from 2016 to 2024.